Monoclonal antibodies are monoclonal antibody drugs, which are molecularly targeted drugs, and are made by using genetic engineering technology to extract monoclonal antibodies from hybridomas in specific mice. Due to the good tolerability and outstanding efficacy of monoclonal antibody drugs, they are mainly used in the adjuvant treatment of some malignant tumors. Monoclonal antibodies act on the antigens related to the membrane differentiation of malignant tumor cells or epidermal growth factor receptors, thus inducing the death of tumor cells, and at the same time inhibit the proliferation of tumor cells by inhibiting tumor angiogenesis or blocking the mediation between tumor cells, and finally control the development of malignant tumors to a certain extent. Commonly used drugs include alemtuzumab, rituximab, etc. In addition, monoclonal antibody drugs can also be used to treat rheumatic immune diseases, including rheumatic fever, rheumatoid arthritis, systemic lupus erythematosus, etc. Monoclonal antibody drugs can effectively improve and relieve the symptoms of the disease, and the commonly used drugs in clinical practice are certolizumab, golimumab, infliximab, etc. It is worth noting that monoclonal antibody drugs also have certain adverse effects, including fever, chills and chills, and may be accompanied by digestive system symptoms, such as nausea, vomiting and diarrhea, and may also induce hypertension. Therefore, patients need to follow the doctor’s instructions and provide timely feedback when adverse reactions occur, and actively cooperate with the treatment to reduce the impact of the drug on the body.